| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised … MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ... The Lancet 395 (10231), 1208-1216, 2020 | 1674 | 2020 |
| Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and … M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ... European urology 70 (6), 926-937, 2016 | 1157 | 2016 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 1056 | 2018 |
| Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution … M Perera, N Papa, M Roberts, M Williams, C Udovicich, I Vela, ... European urology 77 (4), 403-417, 2020 | 896 | 2020 |
| State-of-the-art in force and tactile sensing for minimally invasive surgery P Puangmali, K Althoefer, LD Seneviratne, D Murphy, P Dasgupta IEEE sensors Journal 8 (4), 371-381, 2008 | 701 | 2008 |
| Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy G Novara, JWF Catto, T Wilson, M Annerstedt, K Chan, DG Murphy, ... European urology 67 (3), 376-401, 2015 | 487 | 2015 |
| Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 416 | 2019 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 394 | 2020 |
| Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer D Ilic, SM Evans, CA Allan, JH Jung, D Murphy, M Frydenberg Cochrane Database of Systematic Reviews, 2017 | 341 | 2017 |
| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the … L Emmett, J Buteau, N Papa, D Moon, J Thompson, MJ Roberts, K Rasiah, ... European urology 80 (6), 682-689, 2021 | 321 | 2021 |
| Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial S Siva, M Bressel, DG Murphy, M Shaw, S Chander, J Violet, KH Tai, ... European urology 74 (4), 455-462, 2018 | 321 | 2018 |
| Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data … NJ Sathianathen, A Omer, E Harriss, L Davies, V Kasivisvanathan, ... European urology 78 (3), 402-414, 2020 | 301 | 2020 |
| Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? JP Grummet, M Weerakoon, S Huang, N Lawrentschuk, M Frydenberg, ... BJU international 114 (3), 384-388, 2014 | 284 | 2014 |
| Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 278 | 2020 |
| Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories RA Taylor, M Fraser, J Livingstone, SMG Espiritu, H Thorne, V Huang, ... Nature communications 8 (1), 13671, 2017 | 252 | 2017 |
| Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ... European urology 76 (6), 831-842, 2019 | 251 | 2019 |
| Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis S Memon, AG Heriot, DG Murphy, M Bressel, AC Lynch Annals of surgical oncology 19, 2095-2101, 2012 | 248 | 2012 |
| Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up DG Murphy, M Kerger, H Crowe, JS Peters, AJ Costello European urology 55 (6), 1358-1367, 2009 | 230 | 2009 |
| Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel TG Wilson, K Guru, RC Rosen, P Wiklund, M Annerstedt, BH Bochner, ... European urology 67 (3), 363-375, 2015 | 213 | 2015 |
| Preservation of the neurovascular bundles is associated with improved time to continence after radical prostatectomy but not long-term continence rates: results of a systematic … F Reeves, P Preece, J Kapoor, W Everaerts, DG Murphy, NM Corcoran, ... European urology 68 (4), 692-704, 2015 | 205 | 2015 |
Professor Nathan LawrentschukUniversity of Melbourne, Royal Melbourne Hospital, AustraliaPotvrđena adresa e-pošte na unimelb.edu.au
